VYNE Therapeutics Inc Dossier - Source-backed chat

VYNE Therapeutics Inc

VYNENASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.67

Intrinsic Value $24.50median of 2 methodsbased on filings through 31 Mar 2026

Market Price $28.56Price as of 27 Jul 2026

Near fair valueIntrinsic value is 14% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $19.1M

Enterprise Value −$5.6M

Shares Outstanding 667.7K diluted

Next Earnings Date31 Dec 2027

Last ex-dividend22 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

VYNE Therapeutics is undergoing a transformative reverse merger with privately held Yarrow Bioscience, expected to close in Q3 2026. Post-merger, the combined company will operate as Yarrow Bioscience and trade under the ticker YARW, focusing on YB-101, a potential first-in-class anti-TSHR antibody for Graves' disease and thyroid eye disease. While the pipeline transition offers a highly promising therapeutic target backed by a robust $200 million cash runway, legacy VYNE shareholders face massive dilution, retaining only a ~3% ownership stake in the combined entity. Legacy shareholders will, however, receive a special pre-closing cash dividend of $0.34 to $0.38 per share. Given the imminent corporate restructuring and complete shift in business focus, a Hold recommendation is advised until the merger finalizes and the new clinical programs establish operational momentum.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The reverse merger faces unexpected regulatory or shareholder delays, or the concurrent $100 million pre-closing financing fails to fully close. If the merger is terminated, VYNE's legacy pipeline (which was wound down in anticipation of the merger) leaves the company with limited strategic alternatives, forcing liquidation or highly dilutive emergency financing.

Base CaseCentral scenario

The reverse merger with Yarrow Bioscience closes successfully in Q3 2026. Legacy VYNE shareholders receive the special cash dividend of $0.34 to $0.38 per share and retain a 3% stake in the newly formed YARW. The combined company initiates the Phase 2a/2b trial for YB-101 in Graves' disease, supported by a strong cash runway extending into 2028. The stock trades in line with clinical-stage biotech peers as it approaches its H2 2027 readouts.

Bull CaseUpside scenario

The bull case centers on the successful clinical development of YB-101, a potential first-in-class anti-TSHR monoclonal antibody targeting Graves' disease and thyroid eye disease. Backed by a robust $200 million cash runway extending into 2028, the company is well-positioned to achieve key Phase 2a proof-of-concept readouts in H2 2027, which could establish Yarrow as a leader in thyroid autoimmune diseases and unlock significant long-term valuation upside.

Scenarios reflect our research view at the research date.

Key Investment Merits

Transformative pipeline shift to YB-101, a potential first-in-class anti-TSHR antibody targeting Graves' disease and thyroid eye disease, which have high unmet medical needs.
Substantial post-merger cash runway of approximately $200 million (including committed pre-closing financings) expected to fund operations into 2028.
Immediate capital return to legacy shareholders via a planned pre-closing cash dividend of $14.5 million to $16.5 million ($0.34 to $0.38 per share).
Strong institutional backing from prominent healthcare investors including RTW Investments, OrbiMed, Janus Henderson, and venBio Partners.

Key Investment Risks

Extreme dilution for legacy VYNE shareholders, who will collectively own only approximately 3% of the combined company post-merger.
Complete reliance on a single clinical-stage asset (YB-101) following the wind-down of VYNE's legacy BET inhibitor programs (VYN201 and VYN202).
Clinical development and regulatory risks inherent in transitioning a newly in-licensed asset into Phase 2 trials.
Transaction risk if the merger fails to close, which could lead to company liquidation.

Thesis Invalidation Triggers

Failure to obtain shareholder or regulatory approval for the reverse merger with Yarrow Bioscience.
Inability to secure the committed $100 million pre-closing private financing.
Safety signals or clinical holds placed on YB-101 trials by the FDA.
Termination of the global ex-China licensing agreement for YB-101 with GenSci.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.